AKBA

Arjuna's Novel Natural Blend Helps Give Fast Relief of Workout Pain

Retrieved on: 
Tuesday, May 3, 2022
People, Turmeric, Curcuma, Head, Running, Boswellia, Arjuna, Pain management, Pain, Myalgia, Neck, NRS, Paracetamol, Lists of diseases, Arthralgia, Abdomen, Human, Doctor of Philosophy, Trial of the century, Pressure, Journal, COX2, Lifting, Frankincense, Exertion, Quality of life, Movement, Pelvis, AKBA, Technology, Sport, Exercise, Poultry, Dietary supplement

KOCHI, India, May 3, 2022 /PRNewswire/ -- Results of a new, randomized, placebo-controlled, multicenter study demonstrate Arjuna Natural Pvt. Ltd.'s Rhuleave-K®, a proprietary blend of extracts of turmeric (Curcuma longa) and frankincense (Boswellia serrata) Rhuleave-K® offers natural, rapid relief of acute musculoskeletal pain in multiple body parts following exercise.

Key Points: 
  • Ltd.'s Rhuleave-K , a proprietary blend of extracts of turmeric (Curcuma longa) and frankincense (Boswellia serrata) Rhuleave-K offers natural, rapid relief of acute musculoskeletal pain in multiple body parts following exercise.
  • "People will typically reach for over-the-counter pain relief agents, for managing acute pain because of the swift action," explains Benny Antony, PhD, Joint Managing Director for Arjuna.
  • "Consumers are also increasingly turning to complementary medicine including traditional herbal remedies and natural supplements for pain relief.
  • Pain alleviation could be felt as early as 40 minutes following supplementation, with complete pain relief achieved by as early as 160 minutes.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Rivian, Akebia, Grab, and Celsius and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, May 3, 2022
Grab, Defendant, Mission statement, Offering, Kidney, NASDAQ, GLOBE, Chronic kidney disease, Company, MACE, Annual report, Patient, SUV, Anemia, Adult, Lists of schools in England, AKBA, Register, Phage r1t holin family, R1S, Celsius, Therapy, Program, News, Registration statement, IPO, Real estate, Security (finance), Audit, Pharmaceutical industry, Risk management, Online gambling, Rivian, Akebia, P.C

As a result, the price of the Companys shares was artificially and materially inflated at the time of the Offering.

Key Points: 
  • As a result, the price of the Companys shares was artificially and materially inflated at the time of the Offering.
  • The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and prospects.
  • For more information on the Celsius class action go to: https://bespc.com/cases/CELH
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Akebia Therapeutics to Report First Quarter Financial Results

Retrieved on: 
Monday, May 2, 2022
AKBA, LIVE, Nasdaq, Investor, Therapy, Kidney disease, Video game, Akebia

CAMBRIDGE, Mass., May 2, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the first quarter ended March 31, 2022 on Monday, May 9, 2022 following the close of financial markets.

Key Points: 
  • CAMBRIDGE, Mass., May 2, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the first quarter ended March 31, 2022 on Monday, May 9, 2022 following the close of financial markets.
  • Akebia will host a conference call Monday, May 9, 2022 at 4:30 p.m.
  • ET to discuss its financial results and provide a general business update.
  • Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akebia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – AKBA

Retrieved on: 
Thursday, April 28, 2022
Adult, Securities Exchange Act of 1934, Lists of action films, Patient, GLOBE, Anemia, Pomerantz, Therapy, Chronic kidney disease, Complaint, Court, District court, LLP, Person, Company, Lists of schools in England, News, AKBA, Program, NASDAQ, Defendant, SEC Rule 10b-5, Kidney, MACE, Ext, Pharmaceutical industry, Akebia

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Akebia is a biopharmaceutical company that focuses on the development and commercialization of renal therapeutics for patients with kidney diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

AKEBIA THERAPEUTICS, INC. (NASDAQ: AKBA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Akebia Therapeutics, Inc. (NASDAQ: AKBA)

Retrieved on: 
Thursday, April 28, 2022
Advertising, Adult, Lists of action films, Securities Exchange Act of 1934, Investment, Patient, GLOBE, Anemia, Therapy, Chronic kidney disease, Court, District court, Labour government, Lists of schools in England, NEW, News, AKBA, Program, NASDAQ, The Legal 500, Company, Defendant, Kidney, MACE, Tobacco, Pharmaceutical industry, Risk management, Security (finance), Akebia

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Eastern District of New York and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Akebia is a biopharmaceutical company that focuses on the development and commercialization of renal therapeutics for patients with kidney diseases.
  • If you purchased AKBA securities, and/or would like to discuss your legal rights and options please visit Akebia Therapeutics, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ericsson, C3.ai, Rivian, and Akebia and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, April 28, 2022
International Consortium of Investigative Journalists, AKBA, NASDAQ, Islam, Register, NYSE, Patient, GLOBE, Ericsson, Therapy, ISIS, Complaint, Company, Lists of schools in England, News, MACE, American, Adult, ICIJ, IPO, SUV, Chronic kidney disease, Technology, Partnership, Adoption, R1S, Defendant, American depositary receipt, Baker Hughes, ADS, Anemia, Registration statement, Phage r1t holin family, Program, Compliance, Kidney, Offering, Pharmaceutical industry, Risk management, Real estate, Audit, P.C, Akebia, Rivian

On February 15, 2022, during intraday trading hours, Ericsson issued a press release disclosing media inquiries into its business dealings in Iraq.

Key Points: 
  • On February 15, 2022, during intraday trading hours, Ericsson issued a press release disclosing media inquiries into its business dealings in Iraq.
  • That press release assured investors of the Companys transparency regarding these inquiries, while vaguely alluding to having undertaken its own investigative and compliance efforts.
  • Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and compliance policies.
  • For more information on the Akebia class action go to: https://bespc.com/cases/AKBA
    About Bragar Eagel & Squire, P.C.

ROSEN, A TOP RANKED FIRM, Encourages Akebia Therapeutics, Inc. Investors to Secure Counsel Before Important May 13 Deadline in Securities Class Action – AKBA

Retrieved on: 
Wednesday, April 27, 2022
Titan, I-Space (Chinese company), LinkedIn, NDD, TO, Patient, Twitter, GLOBE, Anemia, Therapy, Court, Class, Advertising, Vadadustat, Lists of schools in England, AKBA, WHY, Facebook, NASDAQ, THE, Online gambling, Insurance, Tobacco, Akebia

WHAT TO DO NEXT: To join the Akebia class action, go to https://rosenlegal.com/submit-form/?case_id=4028 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Akebia class action, go to https://rosenlegal.com/submit-form/?case_id=4028 or call Phillip Kim, Esq.
  • If you wish to serve as lead plaintiff, you must move the Court no later than May 13, 2022.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

AKBA INVESTOR NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA

Retrieved on: 
Monday, April 25, 2022
Titan, Vadadustat, Advertising, Twitter, NASDAQ, WHY, NDD, Court, Anemia, Patient, LinkedIn, Program, Plaintiff, TO, Lists of schools in England, AKBA, Facebook, Class, Therapy, THE, I-Space (Chinese company), Online gambling, Insurance, Tobacco, Akebia

WHAT TO DO NEXT: To join the Akebia class action, go to https://rosenlegal.com/submit-form/?case_id=4028 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Akebia class action, go to https://rosenlegal.com/submit-form/?case_id=4028 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA

Retrieved on: 
Saturday, April 23, 2022
Titan, Vadadustat, Advertising, Twitter, NASDAQ, WHY, NDD, Court, Anemia, Patient, LinkedIn, Program, Plaintiff, TO, Lists of schools in England, AKBA, Facebook, Class, Therapy, THE, I-Space (Chinese company), Online gambling, Insurance, Tobacco, Akebia

WHAT TO DO NEXT: To join the Akebia class action, go to https://rosenlegal.com/submit-form/?case_id=4028 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Akebia class action, go to https://rosenlegal.com/submit-form/?case_id=4028 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Rivian, Akebia, Grab, and Celsius and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, April 23, 2022
R1S, News, Annual report, Grab, IPO, Chronic kidney disease, Adult, NASDAQ, MACE, Anemia, GLOBE, Patient, Offering, Mission statement, Phage r1t holin family, Program, Lists of schools in England, Defendant, Celsius, Company, Kidney, Registration statement, Register, AKBA, SUV, Therapy, Real estate, Security (finance), Audit, Pharmaceutical industry, Risk management, Online gambling, Akebia, Rivian, P.C

As a result, the price of the Companys shares was artificially and materially inflated at the time of the Offering.

Key Points: 
  • As a result, the price of the Companys shares was artificially and materially inflated at the time of the Offering.
  • The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and prospects.
  • For more information on the Celsius class action go to: https://bespc.com/cases/CELH
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.